Trevi Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 10.9 million compared to USD 6.4 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.06 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | -0.77% | +2.80% | +91.79% |
May. 07 | Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.79% | 181M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- TRVI Stock
- News Trevi Therapeutics, Inc.
- Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024